MedPath

Increlex

These highlights do not include all the information needed to use INCRELEX safely and effectively. See full prescribing information for INCRELEX. INCRELEX (mecasermin) injection, for subcutaneous use Initial U.S. Approval: 2005

Approved
Approval ID

d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 7, 2025

Manufacturers
FDA

Eton Pharmaceuticals, Inc.

DUNS: 080870465

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Mecasermin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71863-216
Application NumberBLA021839
Product Classification
M
Marketing Category
C73585
G
Generic Name
Mecasermin
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateMay 7, 2025
FDA Product Classification

INGREDIENTS (7)

MecaserminActive
Quantity: 40 mg in 4 mL
Code: 7GR9I2683O
Classification: ACTIB
BENZYL ALCOHOLInactive
Quantity: 36 mg in 4 mL
Code: LKG8494WBH
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
POLYSORBATE 20Inactive
Code: 7T1F30V5YH
Classification: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9B
Classification: IACT
ACETIC ACIDInactive
Code: Q40Q9N063P
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Increlex - FDA Drug Approval Details